The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind" is generating significant coverage in the Business category, with 9 articles from 9 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Endpoints News, KSL.com, marketscreener.com and The Manila Times. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 46d ago.
Quick answers
Why is "The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kin" trending?
Because 9 independent news sources published 9 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (9)
- #EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy Endpoints News · 48d ago
- Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up KSL.com · 48d ago
- Weight-loss drug developers line up to tap lucrative market as competition heats up marketscreener.com · 48d ago
- Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss The Manila Times · 48d ago
- Pharma deals and data heat the weight-loss-drug market Chemical & Engineering News · 48d ago
- Trevogrumab (anti-myostatin) can help preserve lean mass during and after semaglutide-induced weight loss Medical Xpress · 48d ago
- Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ) Seeking Alpha · 48d ago
- Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial Reuters · 48d ago
- The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind WSJ · 48d ago
Topics
Related trends
Hundreds of children in England prescribed weight-loss jabs, figures show
New figures reveal hundreds of children in England, including under-12s, have been prescribed weight-loss jabs.
The Offshore Wind Industry Gave Him the Well-Paying Work He Needed. Then Trump Gutted It.
Offshore wind industry faces uncertainty after Trump's actions
The Fed chief said AI would tame inflation. His colleagues disagree.
Federal Reserve officials are publicly divided over whether artificial intelligence infrastructure is driving or taming inflation.
Validation of clinical and preclinical obesity across global cohorts
An international study tested a new obesity definition that adds waist measurements to BMI.
Here's Why The Dire Wolf Really Wasn't Brought Back From Extinction, Scientists Argue
Scientists push back on claims that dire wolves have been resurrected, arguing the animals are genetically modified gray wolves, not true de-extinction.
The first study of AI data centers’ climate pollution is here—and it’s a massive undercount
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.